251 286 - Biotech Bayern

Central tasks are:
general coaching and consultancy for business start-ups
regarding economic strategies, business models, scientific
projects, market entrance strategies, patent and brand
strategies, financial strategies, knowledge management,
investor relations, corporate governance, corporate social
responsibility, directives, data protection and IT security
advice and support for business start-ups during
negotiations with investors and financing rounds, also in
the context of negotiations with strategic partners and
licensing or cooperation partners
analysis of potentials of regional business start-ups and
of possible technology-oriented spin-offs
support in the preparation and maintenance of business
plans
advice on matters of company management in business
start-ups
advice on the preparation of finance planning and
liquidity planning
advice on quality management and quality assurance as
well as risk management in business start-ups
advice on the qualification of company founders
regional and supraregional formation of networks;
networking of academic and industrial partners
advice on activities to promote the recruitment of
innovative companies, simultaneously strengthening
cooperation between existing institutions and companies
cooperation in creating and developing a constructive
climate between regional companies and institutions
There are also successes to be reported with regard to the
already established leaseholders of the Würzburg Innovation
and Start-up Center. The pharmaceutical company vaso-
CONTACT
IGZ BioMed/ZmK,
Dr. Gerald Böhm
Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0)931 270 62 94
Internet: www.igz.wuerzburg.de
pharm GmbH, for example, has taken an important step forward
in the development of a drug for the treatment of the
consequences of traumatic brain injury; at the end of 2006,
the substance VAS203 received the approval of the Federal
Institute for Drugs and Medical Devices (Bundesinstitut für
Arzneimittel und Medizinprodukte; BfArM)) for a phase I
clinical study in humans, enabling the start of a corresponding
study in January 2007.
The Würzburg company Patrys GmbH, located on IGZ
BioMed/ZmK premises, is the operative core of the
Australian Patrys Ltd, whose stock exchange debut in 2007
was a remarkable one: owing to its noteworthy floatation on
the Australian Stock Market Exchange, the company now
has � 15 million available. The capital thus acquired could
enable the company to carry out clinical studies for its first
own special-type of antibody for tumour therapy.
In preious years IGZ BioMed/ZmK has done a great deal of
promotional groundwork, also with long-term prospects
of job-relevant success for the location. In the coming years,
further business start-ups are expected from pre-seed promotion
schemes that have already been launched. Another
important aim is to further improve the networking of the
regional technological companies from the health industry,
medical technology, silicate research, plastics technology
and medical imaging. The development of its own unmistakable
and yet innovative profile in the life sciences sector
will have a central role to play in this context. These and
further measures will give further drive to the “Life Sciences
in Würzburg” location project for many years to come.
An attractive location for high-tech business start-ups: the Innovation and
Start-up Center for Biotechnology and Biomedicine/Center for Modern
Communication Technologies (IGZ BioMed/ZmK) in Würzburg
35